United States Food and Drug Administration

Center for Drug Evaluation and Research

10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America

CDERExports@fda.hhs.gov - Telephone (301) 796-4950

Certificate of a Pharmaceutical Product - Active Pharmaceutical Ingredient (API)

Certificate Number: 5W7X-8ANH Certificate Issued Date: December 20, 2024 Certificate Expiration Date: December 20, 2026

Exporting Country: UNITED STATES of AMERICA

1.1 Drug Trade Name, International or National non-proprietary name (as applicable) & dosage form: TROMETAMOL 1.2 Active Ingredient(s) and amount(s) per unit dose (complete quantitative composition is preferred): See Attachments 1.3 Is this product authorized by the certifying authority to be marketed in the certifying country or within the jurisdiction of the certifying regional authority? No 1.4 Is this product actually on the market in the certifying country or within the jurisdiction of the certifying regional authority? Yes 1.4.1 Are there restrictions of sale, distribution or administration of the product specified in the marketing authorization? No 2.B.1 Applicant for certificate name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 2.B.2 Status of Applicant: Manufacturer 2.B.3 Why is marketing authorization lacking? Not Required Remarks: The firm proposes to export the active pharmaceutical ingredients (API) listed above, which when properly labeled with statement "Caution: For further manufacturing, processing or repacking", may be freely marketed in the United States of America at this time. 3.1 Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 3.2 Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes 3.3 Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule 3.4 Has the manufacture of this type of dosage form been inspected? Yes	mpor	Exporting Country: CERTIFIED OF INTERIOR
Is this product authorized by the certifying authority to be marketed in the certifying country or within the jurisdiction of the certifying regional authority? No Is this product actually on the market in the certifying country or within the jurisdiction of the certifying regional authority? Yes 1.4.1 Are there restrictions of sale, distribution or administration of the product specified in the marketing authorization? No 2.B.1 Applicant for certificate name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 2.B.2 Status of Applicant: Manufacturer 2.B.3 Why is marketing authorization lacking? Not Required Remarks: The firm proposes to export the active pharmaceutical ingredients (API) listed above, which when properly labeled with statement "Caution: For further manufacturing, processing or repacking", may be freely market in the United States of America at this time. 3.1 Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 3.2 Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes 3.3 Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	1.1	Drug Trade Name, International or National non-proprietary name (as applicable) & dosage form: TROMETAMOL
1.4 Is this product actually on the market in the certifying country or within the jurisdiction of the certifying regional authority? Yes 1.4.1 Are there restrictions of sale, distribution or administration of the product specified in the marketing authorization? No 2.B.1 Applicant for certificate name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 2.B.2 Status of Applicant: Manufacturer 2.B.3 Why is marketing authorization lacking? Not Required Remarks: The firm proposes to export the active pharmaceutical ingredients (API) listed above, which when properly labeled with statement "Caution: For further manufacturing, processing or repacking", may be freely markete in the United States of America at this time. 3.1 Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 3.2 Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes 3.3 Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	1.2	Active Ingredient(s) and amount(s) per unit dose (complete quantitative composition is preferred): See Attachments
1.4.1 Are there restrictions of sale, distribution or administration of the product specified in the marketing authorization? No 2.B.1 Applicant for certificate name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 2.B.2 Status of Applicant: Manufacturer 2.B.3 Why is marketing authorization lacking? Not Required Remarks: The firm proposes to export the active pharmaceutical ingredients (API) listed above, which when properly labeled with statement "Caution: For further manufacturing, processing or repacking", may be freely market in the United States of America at this time. 3.1 Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 3.2 Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes 3.3 Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	1.3	Is this product authorized by the certifying authority to be marketed in the certifying country or within the jurisdiction of the certifying regional authority? No
2.B.1 Applicant for certificate name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 2.B.2 Status of Applicant: Manufacturer 2.B.3 Why is marketing authorization lacking? Not Required Remarks: The firm proposes to export the active pharmaceutical ingredients (API) listed above, which when properly labeled with statement "Caution: For further manufacturing, processing or repacking", may be freely markete in the United States of America at this time. 3.1 Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 3.2 Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes 3.3 Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	1.4	Is this product actually on the market in the certifying country or within the jurisdiction of the certifying regional authority? Yes
2.B.2 Status of Applicant: Manufacturer 2.B.3 Why is marketing authorization lacking? Not Required Remarks: The firm proposes to export the active pharmaceutical ingredients (API) listed above, which when properly labeled with statement "Caution: For further manufacturing, processing or repacking", may be freely markete in the United States of America at this time. 3.1 Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 3.2 Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes 3.3 Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	1.4.1	Are there restrictions of sale, distribution or administration of the product specified in the marketing authorization? No
2.B.3 Why is marketing authorization lacking? Not Required Remarks: The firm proposes to export the active pharmaceutical ingredients (API) listed above, which when properly labeled with statement "Caution: For further manufacturing, processing or repacking", may be freely markete in the United States of America at this time. 3.1 Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 3.2 Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes 3.3 Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	2.B.1	Applicant for certificate name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America
Remarks: The firm proposes to export the active pharmaceutical ingredients (API) listed above, which when properly labeled with statement "Caution: For further manufacturing, processing or repacking", may be freely markete in the United States of America at this time. 3.1 Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 3.2 Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes 3.3 Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	2.B.2	Status of Applicant: Manufacturer
in the United States of America at this time. 3.1 Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America 3.2 Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes 3.3 Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	2.B.3	Why is marketing authorization lacking? Not Required
Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	Remarks: The firm proposes to export the active pharmaceutical ingredients (API) listed above, which when properly labeled with statement "Caution: For further manufacturing, processing or repacking", may be freely marketed in the United States of America at this time.	
Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	III the	
Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule	3.1	Manufacturer name & address: BioSpectra, 100 Majestic Way, Bangor, PA 18013 United States of America
	3.2	Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? Yes
3.4 Has the manufacture of this type of dosage form been inspected? Yes	3.3	Periodicity of routine inspections (years): Pursuant to section 510(h)(3) of the Federal Food, Drug & Cosmetic Act, Inspections will occur in accordance with a risk-based schedule
	3.4	Has the manufacture of this type of dosage form been inspected? Yes
Do the facilities and operations conform to GMPs as recommended by the WHO? (GMPs including 21 Code of Federal Regulations parts 210, 211, or ICH Q7A): Yes, at time of inspection, site complies with FDA cGMP	3.5	Do the facilities and operations conform to GMPs as recommended by the WHO? (GMPs including 21 Code of Federal Regulations parts 210, 211, or ICH Q7A): Yes, at time of inspection, site complies with FDA cGMP
3.6 Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product undertaken by another party? Yes		

Carole Jones, Division Director

Importing Country: GERMANY

Exports Compliance Branch

Division of Global Drug Distribution and Policy

Office of Drug Security, Integrity & Response

Carolefonia









API

Product Code: TRIS-2257-25 Base Product Code: TRIS-1200

Tris/Tromethamine

EP, GMP, API Grade

TRIS-E04-1224-0000 Lot Number:

Retest Date: 12/31/26 Manufacture Date: 12/01/24 CAS Number: 77-86-1 EC Number: 201-064-4 **NET Weight:** 25kg

Molecular Weight: 121.14 g/mol NH₂C(CH₂OH)₃ Molecular Formula:

Bio Active Grade Level

Caution: For manufacturing, processing, or repacking

Caution: Rx Only

Intended Use Statement: Material in this package is suitable for use as a non-Sterile Active

Pharmaceutical Ingredient manufactured in accordance with the ICH Q7 Good Manufacturing Practice Guide. The material in this package is not suitable to be used as a Sterile or Injectable Active Pharmaceutical Ingredient, Drug Product or Household Item.

Storage Conditions: 15-30°C Preserve in Tight Containers

Manufactured at: 100 Majestic Way, Bangor, PA 18013

100 Majestic Way, Bangor, PA 18013 610.599.3400

Signal Word: Not Applicable Hazard Statements: Not Applicable Precautionary Statements: Not Applicable

Emergency Contact in the USA & Canada: 800.424.9300 Emergency Contact Outside the USA & Canada: 703.527.3887